期刊文献+

联邦他唑仙治疗下呼吸道感染疗效观察 被引量:1

下载PDF
导出
摘要 目的评价联邦他唑仙(哌拉西林/他唑巴坦)治疗下呼吸道感染的临床疗效和安全性。方法62例下呼吸道感染患者随机分为治疗组31例对照组31例,分别应用联邦他唑仙和美罗培南治疗,剂量分别为4.5克,1.0克每日两次治疗平均用药10天并进行了临床细胞学观察。结果联邦他唑仙和美罗培南临床有效率分别为90.3%和93.5%,细菌清除率分别为84.6%和85.7%,不良反应发生率均为3.2%。结论联邦他唑仙是治疗下呼吸道细菌感染高效安全的抗菌药。
出处 《实用心脑肺血管病杂志》 2005年第2期96-97,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献3

二级参考文献7

  • 11,Mouton Y, Leroy O,Beuscart C, et al. Efficacy, safety an d tolerance of paren teral piperacillin/tazobactamin the treatment of patients with lower respirator y tract infections. J Antimicrob Chemother, 1993, 31(Suppl A)∶S87
  • 22,Nowe P. Piperacillin/tazobactam in complicated urinary tract infecti ons. Intens CareMed, 1994, 20(Suppl 3)∶S39
  • 33,Marra P, Reynolds R, Stiver G, et al. Piperacillin/tazobactam ve rsus imipenem : adouble-blind, randomized formulary feasibility study at a major teaching ho spital. DiagnMicrobiol Infect Dis, 1998,31(2)∶355
  • 44,Kuye O, Teal J, Devries VG, et al. Safety profile of pipercillin /tazobactam i n phaseⅠ and Ⅲ clinical studies. J Antimicrob Chem other, 1993, 31(Sup pl A)∶ S113
  • 55,Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. A rch InternMed, 1991, 151(3)∶886
  • 66,Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavula nate withinducibly- and constitutively- expressed class Ⅰ β-lactamases. J Antimi crob chemother,1990, 25(1)∶199
  • 77,StobberinghEE.InvitroeffectofYTR(tazobactam)onplasmidandchromosomallymediatedβ-lactamases.Chemotherapy,1990,36(1)∶209 收稿:1999-09-28修回:2000-01-23

共引文献32

同被引文献12

  • 1张延峰.他唑巴坦钠及其复合制剂[J].河北医药,2005,27(2):116-116. 被引量:6
  • 2Bantar C, Vesco E, Heft C, et al. Replacement of broad spectrum Cephalosporins by piperacillin -tazobactam: impact on sustained high rates of bacterial resistance[ J]. Antimicrob Agents Chemother,2004,48 (2) :392 - 395.
  • 3Lopez tt S,Alarcon T,Delgado T,et al. In vitro activity of β - lactam agents and β- lactamase inhibitors in clinical isolates of acinetobacter banmanni [ J ]. Rev Esp Quiioter, 1999,12(12) :140 - 143.
  • 4Nordmann P. Trends in beta - lactam resistance among Enterobacteriaceae [J]. Clin Infect Dis, 1998,27 ( Suppl 1 ) : S100.
  • 5Luzzaro F, Mantengoli E, Perilli M ,et al. Dynamics of a nosocomial outbreak of muhidrug - resistant Pseudomonas aeruginosa producing the PER - 1 extend - spectrum beta - lactamase[ J]. J Clin Microbiol,2001,39(5 ) : 1865.
  • 6Mal, Ishii Y, Ishiguro M, et al. Cloning and sequencing of the gene encoding Toho -2 ,a class A beta -lactamase preferentially inhibited by tazobactam [ J ]. Antimicrob Agents Chemother, 1998,42(5) : 1181.
  • 7Johnson C A,Kelloway J S,Tonelli A,et al. Single -does pharmackinetics of piperacillin and tazobactam in patients with renal disease[J]. Clin Pharmacol Ther,1992,51 (1):32.
  • 8Wise R, Logan M, Cooper M, et al. Pharmacokinetics and tissue penetration of tazobactam adiministered alone and with piperacillin [ J ]. Antimicrob Agents Chemother, 1992,36(6) : 1997.
  • 9Tricks G. Crystalline tazobactam and its production and use [J]. US Patent : U S 5763603,1998 - 06 - 09.
  • 10金少鸿,胡昌勤,宋丹青,等.他唑巴坦半水合物的制备与应用[J].中国专利:1236781A,1998-06-09.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部